Los Angeles, CACIK 19697644 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
20 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Plains Gp Hldgs L P | 1.27M | $24.35M | 20.8% | 0 | Held |
| 2 | Achieve Life Sciences Inc | 3.79M | $18.82M | 16.1% | 0 | Held |
| 3 | Phathom Pharmaceuticals Inc | 740.9K | $12.29M | 10.5% | +188.0K | Added |
| 4 | Viridian Therapeutics Inc |
| 282.5K |
| $8.79M |
| 7.5% |
| +192.5K |
| Added |
| 5 | Milestone Pharmaceuticals In | 4.12M | $8.32M | 7.1% | −1.01M | Reduced |
| 6 | Kyverna Therapeutics Inc | 666.7K | $6.27M | 5.4% | +666.7K | New |
| 7 | Compass Pathways PLC | 861.8K | $5.95M | 5.1% | +351.8K | Added |
| 8 | Inventiva SA | 1.00M | $4.65M | 4.0% | +1.00M | New |
| 9 | Delcath Sys Inc | 438.5K | $4.43M | 3.8% | 0 | Held |
| 10 | Abeona Therapeutics Inc | 830.8K | $4.38M | 3.7% | −143.2K | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio